SAXS DEVELOPMENT AT STATION F2 AND G1

F2 和 G1 站的 SAXS 开发

• 批准号: 8363571
• 负责人: RICHARD GILLILAN
• 金额: $ 10.17万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8363571
• 关键词: B-Cell Lymphomas; Behavior; Breast Cancer Cell; Collaborations; Denmark; Development; Drug Delivery Systems; Enzymes; Funding; Glutaminase; Goals; Grant; Ionic Strengths; Malignant - descriptor; Malignant Neoplasms; Metabolic; Microfluidics; Names; National Center for Research Resources; Oncogenic; Phase; Principal Investigator; Proteins; Regulation; Research; Research Infrastructure; Resources; Running; Sampling; Solutions; Source; Technology; Temperature; Testing; United States National Institutes of Health; beamline; cost; insight; macromolecule; member; micro-total analysis system; protein structure; rapid growth

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. BioSAXS is a field of rapid growth as SAXS gives direct structural information of macromolecules behavior in solution, insight to solution phase protein structures and proteins oligomeric states. Protein structure and oligomeric state are sensitive to solution conditions such as concentration, temperature, ionic strength and pH. Therefore, it is highly relevant to structurally characterize pharmaceutically relevant biomacromolecules in a large number of solution conditions. Use of Lab-on-a-chip technology (a microfluidic chip) enables structural analysis of biomolecules in a high-throughput fashion, using small amount of samples. See www.bioxtas.org for more details. In collaboration with the developers of this technology, we will be testing microfluidic chips on the F2 and G1 beamlines. Initially we plan to run a number of known protein standards as a test, but the final goal is to gain insight into the mechanism and regulation of a key protein involved in cancer: glutaminase. The metabolic enzyme glutaminase has become a potential drug target against malignant transformation. Recently it was shown that inhibiting this enzyme blocks oncogenic transformation of human breast cancer cells and B lymphoma cells. A microfluidic chip will be used to study the oligomeric states of glutaminase under different conditions and to help understand the mechanism and regulation of the enzyme. Collaborators: List of names of people in Denmark who should be named as collaborators; Martin Nors Pedersen, Josiane Lafleur, Katrine N¿rgaard Toft, Bente Vestergaard. Cerione group members: Sekar Ramachandran, William Katt MacCHESS: Magda M¿ller, S¿ren Nielsen

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 BioSAXS是一个快速增长的领域，因为SAXS提供了溶液中大分子行为的直接结构信息，洞察溶液相蛋白质结构和蛋白质寡聚体状态。蛋白质结构和寡聚状态对溶液条件如浓度、温度、离子强度和pH敏感。因此，在大量溶液条件下对药学相关生物大分子进行结构表征是高度相关的。 芯片实验室技术（微流控芯片）的使用使得能够使用少量样品以高通量方式对生物分子进行结构分析。如需详细信息，请参阅www.bioxtas.org。通过与这项技术的开发人员合作，我们将在F2和G1光束线上测试微流控芯片。最初，我们计划运行一些已知的蛋白质标准品作为测试，但最终目标是深入了解参与癌症的关键蛋白质的机制和调控：转氨酶。 代谢酶谷氨酰胺酶已成为抗恶性转化的潜在药物靶点。最近显示抑制这种酶阻断人乳腺癌细胞和B淋巴瘤细胞的致癌转化。微流控芯片将用于研究不同条件下的转氨酶的寡聚状态，并帮助了解酶的机制和调控。 合作者： 丹麦应被命名为合作者的人的名单;马丁·诺斯·佩德森、乔西亚娜·拉法基、卡特琳·恩加德·托夫特、本特·韦斯特加德。 Cerione小组成员：Sekar Ramachandran、William Katt 麦切斯：玛格达·穆勒，索伦·尼尔森